Is Edwards Lifesciences (EW) overvalued or fairly valued?

MarketChacha shows Edwards Lifesciences's valuation in context — a trailing P/E of about 41.9, a forward P/E of about 26.6, a price-to-book of about 4.9 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Edwards Lifesciences's revenue?

Edwards Lifesciences reported revenue of $6.1B for FY2025, with net profit of $1.1B, per official filings.

What is the share price of Edwards Lifesciences (EW)?

Edwards Lifesciences last traded at $89.71 (-0.1% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Edwards Lifesciences

EW · NYSE · Healthcare · United States

Snapshot

TickerEW

ExchangeNYSE

SectorHealthcare

IndustryMedical Devices

CountryUnited States

Employees16,000

HeadquartersIrvine, United States

Websitewww.edwards.com

Filings tracked16

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Who owns it

Insiders0.2%
Institutions96.0%
Public & other3.8%

1,920 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.10.21%
Vanguard Capital Management LLC6.53%
Vanguard Portfolio Management LLC4.59%
State Street Corporation4.57%
JPMORGAN CHASE & CO3.96%
Wellington Management Group, LLP2.92%
Geode Capital Management, LLC2.68%
Bank Of New York Mellon Corporation2.45%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Over 3 years only 0.46× of reported profit became operating cash — the classic sign that headline earnings may be running ahead of the cash actually generated. Often explained by working capital funding growth; worth a closer look.

Cash conversion0.46×

Net margin trend28.0% → 17.7%

Margin has compressed by about 10.3 points over the period — profitability is trending down.

Growth qualityrev 10% · PAT -13%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

One-off items1 of last 3 yrs

Recent reported profit includes sizeable one-off / non-operating items — the underlying operating trend may differ from the headline.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $1.7B · EPS 0.71

Est. earnings growth +21.8%

Next fiscal year

Rev $7.4B · EPS 3.38

Est. earnings growth +12.6%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$6.1B

Net margin

17.7%

ROE

10.4%

Revenue CAGR (2y)

+10.0%

Profit CAGR (2y)

-12.5%

EPS (FY2025)

1.83

Net profit (FY2025)

$1.1B

Ask MarketChacha about EW

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$6.1B	$1.1B	1.83	17.7%	10.4%
FY2024	$5.4B	$4.2B*	6.97	—	41.8%
FY2023	$5.0B	$1.4B	2.30	28.0%	21.1%

* Net profit includes one-off / non-operating items (e.g. a settlement or accounting gain), so it doesn’t reflect operating performance — net margin is hidden for that period.

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$1.7B	$241.9M	0.42	13.9%
2026Q1	$1.6B	$380.7M	0.66	23.1%
2025Q3	$1.6B	$291.1M	0.50	18.7%
2025Q2	$1.5B	$333.2M	0.56	21.7%
2025Q1	$1.4B	$358.0M	0.61	25.3%
2024Q4	$1.4B	$385.6M	0.65	27.8%
2024Q3	$1.4B	$3.1B*	5.13	—
2024Q2	$1.4B	$366.3M	0.61	26.7%
2024Q1	$1.3B	$351.9M	0.58	26.5%
2023Q4	$1.3B	$369.9M	0.61	29.2%
2023Q3	$1.2B	$384.9M	0.63	31.0%
2023Q2	$1.3B	$307.1M	0.50	24.0%
2023Q1	$1.2B	$340.5M	0.56	27.9%

* Net profit includes one-off / non-operating items (e.g. a settlement or accounting gain), so it doesn’t reflect operating performance — net margin is hidden for that period.

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC8/4/2026
8-K — Results of operations, Exhibits
SEC7/23/2026material
8-K — Executive/director change, Shareholder vote results, Exhibits
SEC5/8/2026material
10-Q filing
SEC5/6/2026
8-K — Executive/director change, Reg FD disclosure
SEC5/4/2026material
8-K — Results of operations, Exhibits
SEC4/23/2026material
10-K filing
SEC2/25/2026
8-K — Results of operations, Exhibits
SEC2/10/2026material
8-K — Reg FD disclosure, Exhibits
SEC1/12/2026material

2025

10-Q filing
SEC11/5/2025
8-K — Results of operations, Exhibits
SEC10/30/2025material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC10/30/2025material
8-K — Other events, Exhibits
SEC8/19/2025material
8-K — Reg FD disclosure, Exhibits
SEC8/6/2025material
10-Q filing
SEC8/6/2025
8-K — Executive/director change
SEC7/25/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.